JAN 15, 2017 8:23 AM PST

New Treatment Success for Multiple Sclerosis

WRITTEN BY: Carmen Leitch

A drug called ocrelizumab has had some success in separate clinical trials. It was able to decrease new attacks in patients with relapsing remitting multiple sclerosis (MS), and in patients with primary progressive MS, the drug halted the progression of new symptoms. The research was conducted by an international team of researchers in three studies, which included Amit Bar-Or and Douglas Arnold of the Montreal Neurological Institute and Hospital of McGill University. The following is an interview with Dr Amit Bar-Or by The International Progressive MS Alliance interviews, from last year.

Multiple sclerosis is a disease of the central nervous system that usually gradually gets worse over time. The cause is still mysterious, and the symptoms can vary widely in affected individuals. In MS, the immune system attacks a part of the nervous system called myelin, a sort of insulation for nerve cells.  

One study, reported in the New England Journal of Medicine, involved 732 patients afflicted by primary progressive MS who received one of three randomized treatment assignments: a placebo, the ocrelizumab drug, or a humanized monoclonal antibody that depletes a type of cell called CD20+ B. The research team confirmed that ocrelizumab had a significant impact on new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS. At twelve weeks, patients on the ocrelizumab had a 32.9 percent disability progression compared to 39.3 percent on placebo. At 24 weeks, the placebo showed a disability progression of 35.7 percent compared to 29.6 for those taking ocrelizumab. And by week 120, patients who took a timed 25-foot walk had worsened by 55.1 per cent in patients taking a placebo compared to a 38.9 percent worsening for patients receiving ocrelizumab.

There was also a reduction in other symptoms; there was a reduction in brain volume and fewer brain lesions in patients given the ocrelizumab treatment.

In other studies involving patients with relapsing remitting MS, it was found that the rate of disease relapse was reduced in patients given ocrelizuma by 46 percent in one study and by 47 percent in the other. Ocrelizuma also reduced new brain lesions in these patients and lessened the risk of  disability progression.

"The results in patients with relapsing remitting MS not only demonstrate very high efficacy against relapses, but also underscore the important emerging role of B cells of the immune system in the development of relapses," explained Bar-Or. "While the results in patients with primary progressive MS are more modest, they nonetheless represent the very first successful trial in such patients, a breakthrough as primary progressive MS now transitions from a previously untreatable condition to one that can be impacted by therapy. It is an important step forward in the field,” he concluded.

Douglas Arnold, left, and Amit Bar-Or, right, authors on the three studies / Credit: The Neuro

Sources: AAAS/Eurekalert! via McGill University, National Multiple Sclerosis SocietyNew England Journal of Medicine

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAY 02, 2021
Cell & Molecular Biology
Coral Cells Can Spit Out the Symbionts They Don't Want
MAY 02, 2021
Coral Cells Can Spit Out the Symbionts They Don't Want
Some microalgae are symbionts, like dinoflagellates that live in coral. A symbiotic sea anemone is seen in this image by ...
MAY 06, 2021
Genetics & Genomics
There's More to Viral DNA Than ATGC
MAY 06, 2021
There's More to Viral DNA Than ATGC
Plants and animals have genomes made of four nucleotide bases, adenine (A), thymine (T), cytosine (C), and guanine (G). ...
MAY 28, 2021
Genetics & Genomics
Some Biofilms Seem to Activate Cancer Genes
MAY 28, 2021
Some Biofilms Seem to Activate Cancer Genes
New research assessed bacterial and fungal biofilms, tenacious microbial communities that are tougher than small groups ...
MAY 31, 2021
Genetics & Genomics
Gene Expression is Different in Two Parts of the Hippocampus
MAY 31, 2021
Gene Expression is Different in Two Parts of the Hippocampus
The hippocampus is a region of the brain thought to play a role in many different neurological and psychiatric disorders ...
JUN 04, 2021
Cell & Molecular Biology
Even When They're Outside the Brain, Infections Worsen Alzheimer's
JUN 04, 2021
Even When They're Outside the Brain, Infections Worsen Alzheimer's
It's thought that inflammation is closely connected to cognitive decline, and neuroinflammation plays a role role in the ...
JUN 20, 2021
Cell & Molecular Biology
What Triggers a Sneeze?
JUN 20, 2021
What Triggers a Sneeze?
For most of us, a whiff of pepper or tickle in the nose will trigger a sneeze. The action can rapidly expel whatever mig ...
Loading Comments...